Restricted accessResearch articleFirst published online 2012-12
Short Communication: Factors Influencing Time to CD4 + T Cell Counts >200 Cells/mm 3 in HIV-Infected Individuals with CD4 + T Cell <50 Cells/mm 3 at the Time of Starting Combination Antiretroviral Therapy
We evaluated factors influencing time to CD4+ T cell counts >200 cells/mm3 in HIV-infected individuals with CD4+ T cell <50 cells/mm3 starting combination antiretroviral therapy (cART). We included a total of 29 patients on successful cART for more than 1 year. In a logistic regression model, higher pre-cART CD4+ T cell counts were significantly associated with shorter time to CD4+ T cell counts >200cells/mm3 in HIV-infected individuals with baseline CD4+ T cell <50 cells/mm3. In survival analysis, patients having higher pre-cART CD4+ T cell counts, especially 40–49 cells/mm3, were at significantly higher risk of achieving CD4+ T cell counts >200 cells/mm3.
Get full access to this article
View all access options for this article.
References
1.
HammerSM, SaagMS, SchechterMet al.Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA, 2006; 296,7:827–843.
2.
AbaasaAM, ToddJ, EkoruKet al.Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: The experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res, 2008; 8:241.
3.
HallHI, McDavidK, LingQ, SloggettA. Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol, 2006; 16,11:824–833.
4.
Missed opportunities for earlier diagnosis of HIV infection–South Carolina, 1997–2005. MMWR Morb Mortal Wkly Rep, 2006; 55,47:1269–1272.
5.
MarksG, CrepazN, JanssenRS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS, 2006; 20,10:1447–1450.
6.
AbergJA, KaplanJE, LibmanHet al.Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis, 2009; 49,5:651–681.
7.
MofensonLM, BradyMT, DannerSPet al.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep, 2009; 58,RR-11:1–166.
8.
HoggRS, YipB, ChanKJet al.Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA, 2001; 286,20:2568–2577.
9.
SteinDS, KorvickJA, VermundSH. CD4+ lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: A review. J Infect Dis, 1992; 165,2:352–363.
10.
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents adults. MMWR Recomm Rep, 1992; 41,RR-17:1–19.
11.
LeeJH, KimGJ, ChoiBSet al.Increasing late diagnosis in HIV infection in South Korea: 2000–2007. BMC Public Health, 2010; 10:411.
12.
NotermansDW, PakkerNG, HamannDet al.Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis, 1999; 180,4:1050–1056.
13.
StaszewskiS, MillerV, SabinCet al.Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS, 1999; 13,8:951–956.
14.
Cozzi LepriA, PhillipsAN, d'Arminio MonforteAet al.When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study. AIDS, 2001; 15,8:983–990.
15.
PhillipsAN, StaszewskiS, WeberRet al.HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA, 2001; 286,20:2560–2567.
16.
AliyuMH, SalihuHM. Tuberculosis and HIV disease: Two decades of a dual epidemic. Wien Klin Wochenschr, 2003; 115,19–20:685–697.
17.
KizzaHM, RodriguezB, Quinones-MateuMet al.Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clin Diagn Lab Immunol, 2005; 12,11:1298–1304.
18.
LeeJH, LeeEJ, KimSS, NamJG, WhangJ, KeeMK. Epidemiological characteristics of HIV-infected women in the Republic of Korea: A low HIV prevalence country. J Public Health Policy, 2009; 30,3:342–355.
